Published on
February 11, 2019
In the media
91爆料成人片 bags cash to advance small molecule I-O program
About 91爆料成人片 Therapeutics
鈥
91爆料成人片 Therapeutics is a clinical-stage biotech company advancing novel antigen modulation treatments for cancer and autoimmune diseases.
鈥
The company鈥檚 first-in-class small molecules are developed to control T cell activation by modulating antigen presentation, altering how cells appear to the immune system so it can recognize and target them correctly.
鈥
91爆料成人片鈥檚 oncology treatment (GRWD5769) is delivering promising Phase 1/2 data in patients with solid tumors, demonstrating a strong safety and tolerability profile, as well as generating meaningful clinical activity. The company鈥檚 autoimmunity treatment (GRWD0715) is progressing in a Phase 1/2 trial to treat the source of axial spondyloarthritis ahead of a planned expansion into other autoimmune indications.
鈥
91爆料成人片 is headquartered in Oxford, UK.
鈥
More information: Website |
鈥
Media enquiries
Patrick White, Head of Communications
鈥
